Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

David Wyles

Concepts (239)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
58
2025
706
11.480
 Why?
Hepatitis C, Chronic
31
2025
154
8.770
 Why?
Hepacivirus
46
2024
235
7.880
 Why?
Hepatitis C
27
2025
234
7.670
 Why?
Benzimidazoles
16
2020
158
4.380
 Why?
Drug Resistance, Viral
17
2018
111
3.280
 Why?
HIV Infections
28
2022
2715
3.140
 Why?
Coinfection
15
2020
133
3.140
 Why?
Ribavirin
15
2020
92
2.410
 Why?
Sofosbuvir
16
2022
58
2.350
 Why?
Quinoxalines
7
2019
65
2.330
 Why?
Sulfonamides
13
2020
500
2.300
 Why?
Fluorenes
7
2020
40
2.300
 Why?
Liver Cirrhosis
8
2020
275
2.250
 Why?
Viral Nonstructural Proteins
9
2018
58
2.010
 Why?
Drug Therapy, Combination
26
2020
1013
1.880
 Why?
Uridine Monophosphate
5
2016
15
1.740
 Why?
Carbamates
9
2020
45
1.510
 Why?
Anti-Retroviral Agents
5
2019
230
1.480
 Why?
Protease Inhibitors
10
2020
104
1.420
 Why?
Hepatitis B, Chronic
3
2019
18
1.390
 Why?
Proline
11
2020
78
1.300
 Why?
Pyrrolidines
9
2019
69
1.240
 Why?
Congresses as Topic
3
2021
215
1.210
 Why?
Hepatitis, Viral, Human
3
2021
25
1.190
 Why?
Genotype
19
2022
1832
1.020
 Why?
Cyclopropanes
11
2020
88
1.000
 Why?
Drug Users
2
2024
42
0.990
 Why?
Sustained Virologic Response
10
2020
37
0.950
 Why?
Lactams, Macrocyclic
10
2020
49
0.930
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
19
0.830
 Why?
HIV-1
8
2020
842
0.800
 Why?
Virus Replication
7
2012
444
0.770
 Why?
Disease Eradication
1
2020
4
0.720
 Why?
Organophosphonates
4
2011
91
0.700
 Why?
Homosexuality, Male
2
2021
176
0.690
 Why?
Anti-HIV Agents
6
2020
748
0.670
 Why?
Humans
75
2025
129136
0.660
 Why?
Valine
7
2020
74
0.650
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.570
 Why?
Imidazoles
2
2015
229
0.560
 Why?
Ritonavir
6
2020
72
0.550
 Why?
Darunavir
1
2017
17
0.550
 Why?
Treatment Failure
5
2019
343
0.540
 Why?
Aminoisobutyric Acids
5
2019
7
0.530
 Why?
Uracil
5
2020
30
0.520
 Why?
Treatment Outcome
18
2023
10227
0.510
 Why?
Antiretroviral Therapy, Highly Active
3
2015
266
0.510
 Why?
Leucine
5
2019
108
0.500
 Why?
Anilides
5
2020
73
0.500
 Why?
Middle Aged
30
2025
31080
0.500
 Why?
Education, Medical, Continuing
1
2016
124
0.480
 Why?
Male
39
2025
63203
0.470
 Why?
Biomedical Research
1
2021
647
0.470
 Why?
Adenine
4
2020
255
0.460
 Why?
RNA, Viral
7
2015
617
0.460
 Why?
Oligopeptides
2
2013
258
0.450
 Why?
Pyridazines
1
2014
50
0.440
 Why?
Viral Load
7
2020
450
0.440
 Why?
2-Naphthylamine
5
2020
7
0.430
 Why?
Macrocyclic Compounds
3
2019
10
0.430
 Why?
Adult
29
2025
35513
0.420
 Why?
Female
37
2025
68519
0.420
 Why?
Purines
1
2014
169
0.420
 Why?
Quinolines
1
2014
154
0.410
 Why?
Replicon
3
2009
14
0.410
 Why?
Liver
1
2021
1833
0.400
 Why?
Disease Management
1
2016
593
0.390
 Why?
Scavenger Receptors, Class B
1
2012
11
0.390
 Why?
Aged
17
2024
22090
0.370
 Why?
Retreatment
2
2021
70
0.350
 Why?
Drug Synergism
3
2008
359
0.340
 Why?
Acquired Immunodeficiency Syndrome
2
2020
222
0.300
 Why?
Dideoxynucleosides
2
2005
20
0.300
 Why?
Liver Diseases
2
2016
285
0.300
 Why?
Interferon-alpha
4
2013
192
0.290
 Why?
Cytokines
1
2015
1987
0.280
 Why?
Amino Acid Substitution
2
2018
281
0.270
 Why?
Global Health
2
2020
328
0.270
 Why?
Cytosine
2
2009
46
0.260
 Why?
Hepatitis B virus
2
2019
35
0.240
 Why?
HIV
2
2019
226
0.230
 Why?
Mass Screening
3
2023
1159
0.230
 Why?
Hepatitis
1
2004
47
0.230
 Why?
Herpes Simplex
1
2005
93
0.230
 Why?
Alanine
2
2021
141
0.220
 Why?
Prevalence
3
2019
2565
0.210
 Why?
Interferons
2
2015
192
0.200
 Why?
Young Adult
10
2019
12389
0.200
 Why?
Hospitals
2
2024
632
0.200
 Why?
Mutation, Missense
3
2014
318
0.200
 Why?
Interferon beta-1a
1
2021
12
0.190
 Why?
Hepatitis A
1
2021
25
0.180
 Why?
Adenosine Monophosphate
1
2021
62
0.180
 Why?
Tenofovir
2
2020
231
0.180
 Why?
Hepatitis B
1
2021
61
0.180
 Why?
World Health Organization
1
2020
110
0.170
 Why?
Disease Progression
2
2019
2613
0.170
 Why?
Data Interpretation, Statistical
2
2018
335
0.170
 Why?
Polyethylene Glycols
2
2015
597
0.160
 Why?
United States
10
2025
13941
0.160
 Why?
Ribosomes
2
2010
164
0.150
 Why?
Esters
2
2009
74
0.150
 Why?
CD4 Lymphocyte Count
2
2017
267
0.150
 Why?
Immunologic Factors
1
2020
229
0.150
 Why?
Nucleic Acid Conformation
4
2014
706
0.140
 Why?
Hospitalization
2
2024
2077
0.140
 Why?
Alanine Transaminase
1
2018
150
0.140
 Why?
DNA, Viral
1
2019
348
0.140
 Why?
Genes, Viral
1
2016
81
0.130
 Why?
DNA Mutational Analysis
1
2018
386
0.130
 Why?
Mutation
2
2018
3700
0.130
 Why?
Molecular Structure
2
2008
466
0.130
 Why?
High-Throughput Nucleotide Sequencing
2
2016
485
0.130
 Why?
Patient Compliance
1
2020
562
0.130
 Why?
Survival Analysis
1
2019
1265
0.130
 Why?
Adolescent
5
2022
20302
0.130
 Why?
Dose-Response Relationship, Drug
2
2017
1945
0.120
 Why?
Opiate Substitution Treatment
1
2016
137
0.120
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
20
0.120
 Why?
AIDS-Related Opportunistic Infections
1
2015
121
0.120
 Why?
Chemokines
1
2015
222
0.110
 Why?
Chemokine CXCL10
1
2014
34
0.110
 Why?
Drug Interactions
1
2015
360
0.110
 Why?
Phenylenediamines
1
2013
9
0.110
 Why?
Viral Proteins
2
2014
321
0.110
 Why?
Fibrosis
1
2016
522
0.110
 Why?
Prognosis
2
2019
3788
0.110
 Why?
Quality of Life
1
2025
2694
0.100
 Why?
Microbial Sensitivity Tests
2
2012
336
0.100
 Why?
Drug Combinations
3
2019
329
0.100
 Why?
Drug Discovery
1
2013
130
0.100
 Why?
Administration, Oral
1
2014
759
0.100
 Why?
Mental Disorders
1
2020
1010
0.090
 Why?
Cohort Studies
5
2024
5407
0.090
 Why?
Telemedicine
1
2020
783
0.090
 Why?
Case-Control Studies
2
2017
3342
0.090
 Why?
Models, Molecular
3
2012
1483
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
256
0.090
 Why?
Prodrugs
1
2011
45
0.090
 Why?
Nucleosides
1
2010
26
0.090
 Why?
Japan
2
2021
98
0.090
 Why?
Riboswitch
1
2012
68
0.090
 Why?
Prospective Studies
4
2023
7079
0.080
 Why?
Drug Administration Schedule
3
2017
758
0.080
 Why?
Cell Line, Tumor
2
2008
3188
0.080
 Why?
Risk Assessment
1
2019
3260
0.080
 Why?
Drug Design
1
2010
155
0.080
 Why?
Biomarkers
1
2020
3897
0.080
 Why?
Cell Line
2
2012
2737
0.080
 Why?
Piperidines
1
2010
190
0.080
 Why?
Body Mass Index
1
2017
2266
0.080
 Why?
Practice Guidelines as Topic
1
2016
1493
0.080
 Why?
Phenylthiourea
1
2008
5
0.070
 Why?
Immunity, Innate
1
2014
805
0.070
 Why?
Plasmids
1
2009
357
0.070
 Why?
Structure-Activity Relationship
1
2009
531
0.070
 Why?
Inhibitory Concentration 50
1
2006
81
0.070
 Why?
Luciferases
1
2006
148
0.070
 Why?
Genes, Reporter
1
2006
266
0.060
 Why?
Thailand
1
2025
16
0.060
 Why?
Pandemics
2
2024
1492
0.060
 Why?
Saquinavir
1
2004
1
0.060
 Why?
Simplexvirus
1
2005
80
0.060
 Why?
Indinavir
1
2004
7
0.060
 Why?
Uganda
1
2025
72
0.060
 Why?
Nelfinavir
1
2004
9
0.060
 Why?
Drug Labeling
1
2005
40
0.060
 Why?
Nevirapine
1
2004
16
0.060
 Why?
Oxazines
1
2004
27
0.060
 Why?
Benzoxazines
1
2004
31
0.060
 Why?
Lopinavir
1
2004
30
0.060
 Why?
Brazil
1
2025
154
0.060
 Why?
Time Factors
1
2015
6518
0.060
 Why?
Alkynes
1
2004
54
0.060
 Why?
Zidovudine
1
2004
77
0.060
 Why?
Liver Function Tests
1
2004
109
0.060
 Why?
Pregnancy
1
2017
6375
0.060
 Why?
Reverse Transcriptase Inhibitors
1
2004
81
0.060
 Why?
South Africa
1
2025
192
0.060
 Why?
Transfection
1
2006
896
0.060
 Why?
Carcinoma, Hepatocellular
1
2006
271
0.060
 Why?
Bone Marrow Transplantation
1
2005
268
0.060
 Why?
Pyrimidinones
1
2004
102
0.060
 Why?
Recombinant Fusion Proteins
1
2006
635
0.060
 Why?
Double-Blind Method
2
2021
1865
0.050
 Why?
Polyphosphates
1
2022
37
0.050
 Why?
Republic of Korea
1
2021
28
0.050
 Why?
Singapore
1
2021
20
0.050
 Why?
Dried Blood Spot Testing
1
2022
91
0.050
 Why?
Liver Neoplasms
1
2006
643
0.050
 Why?
Retrospective Studies
5
2019
14571
0.050
 Why?
Emergency Service, Hospital
2
2023
1973
0.050
 Why?
Protein Biosynthesis
2
2014
397
0.050
 Why?
Mexico
1
2021
190
0.050
 Why?
Raltegravir Potassium
1
2019
17
0.040
 Why?
Intensive Care Units
1
2024
719
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
71
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
90
0.040
 Why?
Drug Resistance, Multiple, Viral
1
2017
11
0.030
 Why?
Longitudinal Studies
1
2024
2716
0.030
 Why?
Kinetics
1
2020
1617
0.030
 Why?
Oxygen
1
2021
902
0.030
 Why?
Medicaid
1
2020
437
0.030
 Why?
Program Evaluation
1
2020
876
0.030
 Why?
Incidence
2
2013
2635
0.030
 Why?
RNA
1
2022
883
0.030
 Why?
Cell-Free System
1
2014
47
0.030
 Why?
Hepatitis C Antibodies
1
2014
9
0.030
 Why?
Spain
1
2014
36
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
816
0.030
 Why?
Polymorphism, Genetic
1
2017
639
0.030
 Why?
Patient Acceptance of Health Care
1
2020
767
0.030
 Why?
Aged, 80 and over
2
2019
7066
0.030
 Why?
Patient Reported Outcome Measures
1
2017
369
0.030
 Why?
Risk Factors
2
2020
9769
0.030
 Why?
Withholding Treatment
1
2013
70
0.030
 Why?
Patient Care
1
2014
110
0.030
 Why?
Early Diagnosis
1
2014
236
0.030
 Why?
Plasma
1
2014
201
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2012
177
0.020
 Why?
Virus Internalization
1
2010
46
0.020
 Why?
Ligands
1
2012
614
0.020
 Why?
Recombinant Proteins
1
2013
1284
0.020
 Why?
Pilot Projects
1
2015
1567
0.020
 Why?
Magnesium
1
2009
151
0.020
 Why?
Lamivudine
1
2009
61
0.020
 Why?
Genome, Viral
1
2009
127
0.020
 Why?
Referral and Consultation
1
2014
732
0.020
 Why?
Logistic Models
1
2013
1979
0.020
 Why?
Phenotype
1
2014
3058
0.020
 Why?
Base Sequence
1
2009
2135
0.020
 Why?
Severity of Illness Index
1
2013
2739
0.020
 Why?
Randomized Controlled Trials as Topic
1
2011
1363
0.010
 Why?
Mice, Transgenic
1
2009
2079
0.010
 Why?
Animals
2
2018
34610
0.010
 Why?
Substance-Related Disorders
1
2011
1013
0.010
 Why?
Signal Transduction
1
2009
4838
0.010
 Why?
Mice
1
2009
16652
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (239) concept(s)
_
Co-Authors Expand Description
See all (18) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)